SOLICITATION NOTICE
65 -- Justification for Other than Full and Open Competition
- Notice Date
- 12/13/2017
- Notice Type
- Justification and Approval (J&A)
- NAICS
- 325412
— Pharmaceutical Preparation Manufacturing
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- 200-2017-94414
- Archive Date
- 12/28/2017
- Point of Contact
- Christina E. McMillian, Phone: 7704882697, Alan W Sims, Phone: 770-488-2896
- E-Mail Address
-
wpn6@cdc.gov, auy0@cdc.gov
(wpn6@cdc.gov, auy0@cdc.gov)
- Small Business Set-Aside
- N/A
- Award Number
- 200-2017-94414
- Award Date
- 6/29/2017
- Description
- Identification of the statutory authority permitting other than full and open competition: The acquisition is conducted under the authority of 41 United States Code (U.S.C.) 253 (c) (_1_) as set forth in Federal Acquisition Regulation (FAR) 6.302-_1_ Name of the proposed contractor(s): GlaxoSmithKline (GSK) Nature of the acquisition and proposed unique qualifications of the contractor(s): This acquisition is to add the new herpes zoster subunit (HZ/su) vaccine, SHINGRIX®, to the existing GSK adult contract 200-2017-94414 in light of the recent Advisory Committee on Immunization Practices (ACIP) recommendations. SHINGRIX® vaccine is a new herpes zoster subunit (HZ/su) vaccine used to prevent Shingles-a painful, blistering rash that can lead to complications and long term pain. Shingles is more common in older adults and in people who have weak immune systems. Anyone who has ever had chickenpox can develop shingles. Most adults in the United States had chickenpox when they were children, before the advent of the routine childhood vaccination that now protects against chickenpox. On October 25, 2017, based on clinical trials demonstrating superior efficacy to Zoster Vaccine Live (ZVL), ACIP voted that herpes zoster subunit (HZ/su) vaccine is: • recommended for the prevention of herpes zoster and related complications for immunocompetent adults aged 50 years and older • recommended for the prevention of herpes zoster and related complications for immunocompetent adults who previously received zoster vaccine live • recommended the herpes zoster subunit (HZ/su) vaccine rather than the only currently available Zoster Vaccine Live (ZVL) for the prevention of herpes zoster and related complications CDC provides adult vaccine based exclusively on ACIP recommendations. GSK's SHINGRIX® product is the only herpes zoster subunit (HZ/su) vaccine on the market and therefore the only vaccine that can support ACIP recommendations. CDC must add SHINGRIX® to the current GSK contract to support ACIP requirements in preventing Shingles and its serious deleterious effects on adults 50 years and older. Project description: This acquisition is to add the new herpes zoster subunit (HZ/su) vaccine, SHINGRIX®, to the existing GSK adult contract 200-2017-94414 in light of the recent Advisory Committee on Immunization Practices (ACIP) recommendations. Any interested party may respond by Wednesday, December 27, 2017 at 12:00 PM EST to Christina McMillian via e-mail at wpn6@cdc.gov.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/200-2017-94414/listing.html)
- Record
- SN04766058-W 20171215/171213231443-0875121d89142fa696deebe8cff079c7 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |